Literature DB >> 25015287

Generation and identification of tumor-evoked regulatory B cells.

Arya Biragyn1, Catalina Lee-Chang, Monica Bodogai.   

Abstract

The involvement of Bregs in cancer remains poorly understood despite their well-documented regulation of responses to the self and protection from harmful autoimmunity. We recently discovered a unique regulatory B cell subset evoked by breast cancer to mediate protection of metastasizing cancer cells. These results together with the wealth of findings of the last 40 years on B cells in tumorigenesis suggest the existence of additional cancer Bregs modulating anticancer responses. To facilitate the search for them, here we provide our detailed protocol for the characterization and generation of tumor-evoked regulatory B cells. Wherever applicable, we also discuss nuances and uniqueness of a Breg study in cancer to warn potential pitfalls.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25015287      PMCID: PMC4155503          DOI: 10.1007/978-1-4939-1161-5_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  24 in total

1.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 2.  MDSC in autoimmunity.

Authors:  James G Cripps; James D Gorham
Journal:  Int Immunopharmacol       Date:  2011-02-21       Impact factor: 4.932

3.  Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.

Authors:  Qing Ding; Melissa Yeung; Geoffrey Camirand; Qiang Zeng; Hisaya Akiba; Hideo Yagita; Geetha Chalasani; Mohamed H Sayegh; Nader Najafian; David M Rothstein
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

4.  Characterization of stem cell-like cancer cells in immune-competent mice.

Authors:  Jorg A Kruger; Charles D Kaplan; Yunping Luo; He Zhou; Dorothy Markowitz; Rong Xiang; Ralph A Reisfeld
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

5.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

6.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

8.  CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells.

Authors:  P A Monach; H Schreiber; D A Rowley
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

9.  A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.

Authors:  Koichi Yanaba; Jean-David Bouaziz; Karen M Haas; Jonathan C Poe; Manabu Fujimoto; Thomas F Tedder
Journal:  Immunity       Date:  2008-05       Impact factor: 31.745

10.  Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α.

Authors:  Katarzyna Wejksza; Catalina Lee-Chang; Monica Bodogai; Jessica Bonzo; Frank J Gonzalez; Elin Lehrmann; Kevin Becker; Arya Biragyn
Journal:  J Immunol       Date:  2013-02-13       Impact factor: 5.422

View more
  5 in total

1.  TGF-βR inhibitor SB431542 restores immune suppression induced by regulatory B-T cell axis and decreases tumour burden in murine fibrosarcoma.

Authors:  Kavitha Premkumar; Bhavani S Shankar
Journal:  Cancer Immunol Immunother       Date:  2020-07-13       Impact factor: 6.968

2.  Activation of glioma cells generates immune tolerant NKT cells.

Authors:  Bo Tang; Wei Wu; Xiaowei Wei; Yang Li; Gang Ren; Wenhai Fan
Journal:  J Biol Chem       Date:  2014-10-23       Impact factor: 5.157

3.  Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer.

Authors:  Melissa Carpenter; Dolly Chowdhury; Priya Krishna; Sandy Ng; Laura C D Pomatto-Watson; Monica Bodogai; Oye Bosompra; Jonathan Kato; Sarah Wong; Carlos Reyes-Sepulveda; Michel Bernier; Nathan L Price; Arya Biragyn; Rafael de Cabo
Journal:  Geroscience       Date:  2022-08-23       Impact factor: 7.581

Review 4.  Crosstalk of carcinoembryonic antigen and transforming growth factor-β via their receptors: comparing human and canine cancer.

Authors:  Erika Jensen-Jarolim; Judit Fazekas; Josef Singer; Gerlinde Hofstetter; Kumiko Oida; Hiroshi Matsuda; Akane Tanaka
Journal:  Cancer Immunol Immunother       Date:  2015-04-02       Impact factor: 6.968

Review 5.  Positive and negative functions of B lymphocytes in tumors.

Authors:  Meng Shen; Qian Sun; Jian Wang; Wei Pan; Xiubao Ren
Journal:  Oncotarget       Date:  2016-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.